Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma
Liting Zhong(Ganzhou People's Hospital), Chuanhui Cao(Nanfang Hospital), Weiwei Peng(Ganzhou People's Hospital), Hailong Sheng(Nanfang Hospital), Jingyuan Sun(Nanfang Hospital), Yi Wu(Ganzhou People's Hospital), Yongyi Luo(Nanfang Hospital), Tonggang Zhou(Ganzhou People's Hospital), Chaoming Zhou(Ganzhou People's Hospital)
Cited by 2
Related Papers
The Long Intergenic Noncoding RNA UFC1, a Target of MicroRNA 34a, Interacts With the mRNA Stabilizing Protein HuR to Increase Levels of β-Catenin in HCC Cells
|Gastroenterology|2014|231
ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
|Journal for ImmunoTherapy of Cancer|2020|225
miR-139-5p inhibits aerobic glycolysis, cell proliferation, migration, and invasion in hepatocellular carcinoma via a reciprocal regulatory interaction with ETS1
|Oncogene|2018|142
SNHG3 correlates with malignant status and poor prognosis in hepatocellular carcinoma
|Tumor Biology|2015|99
UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation
|Journal of Experimental & Clinical Cancer Research|2020|97